

BIOCRYST PHARMACEUTICALS INC  
Form SC 13G  
January 09, 2017

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**SCHEDULE 13G**

Under the Securities Exchange Act of 1934

BioCryst Pharmaceuticals, Inc.

(Name of Issuer)

Common stock, par value \$0.01

(Title of Class of Securities)

09058V103

(CUSIP Number)

December 29, 2016

(Date of Event Which Requires Filing of this Statement)

Check the following box to designate the rule pursuant to which the Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 09058V103

**Names of Reporting Persons**

**I.R.S. Identification Nos. of  
above persons (entities only)**

1. D. E. Shaw & Co., L.P.

13-3695715

- Check the Appropriate Box**  
2. **if a Member of a Group (See  
Instructions)**

(a)

(b)

**SEC Use Only**

- 3.

**Citizenship or Place of  
Organization**

4. Delaware

**Number  
of**

**Shares**

**Beneficially** **Sole Voting Power**

**Owned**  
by <sup>5.</sup>

**Each** -0-

**Reporting**

**Person**  
**With**

6. **Shared Voting Power**

3,652,607

**Sole Dispositive Power**

7. -0-

**Shared Dispositive Power**

8. 3,690,207

**Aggregate Amount  
Beneficially Owned by Each  
Reporting Person**

9.  
3,690,207

**Check if the Aggregate  
Amount in Row (9) Excludes  
Certain Shares (See  
10. Instructions) [  ]**

**Percent of Class Represented  
by Amount in Row (9)**

11. 5.0%<sup>1</sup>

**Type of Reporting Person  
12. (See Instructions)**

IA, PN

<sup>1</sup> On December 29, 2016, D. E. Shaw & Co., L.P. and Mr. David E. Shaw (collectively, the “Reporting Persons”) became the beneficial owners of more than 5% of the class of securities. On December 30, 2016, the Reporting Persons ceased to be beneficial owners of more than 5% of the class of securities. On January 4, 2017, the Reporting Persons again became beneficial owners of more than 5% of the class of securities. The beneficial ownership information provided in this document is current as of January 4, 2017.

CUSIP No. 09058V103

**Names of Reporting Persons**

**I.R.S. Identification Nos. of  
1. above persons (entities only)**

David E. Shaw

**Check the Appropriate Box  
2. if a Member of a Group (See  
Instructions)**

(a)

(b)

**SEC Use Only  
3.**

**Citizenship or Place of  
Organization**

**4.** United States

**Number  
of**

**Shares**

**Beneficially ~~Sole~~ Voting Power**

**Owned  
by <sup>5.</sup>**

**Each** -0-

**Reporting**

**Person  
With**

**6. Shared Voting Power**

3,652,607

**Sole Dispositive Power**

7. -0-

**Shared Dispositive Power**

8. 3,690,207

**Aggregate Amount  
Beneficially Owned by Each  
Reporting Person**

9.  
3,690,207

**Check if the Aggregate  
Amount in Row (9) Excludes  
Certain Shares (See**

10. **Instructions) [  ]**

**Percent of Class Represented  
by Amount in Row (9)**

11. 5.0%<sup>2</sup>

**Type of Reporting Person  
(See Instructions)**

12.  
IN

<sup>2</sup> On December 29, 2016, D. E. Shaw & Co., L.P. and Mr. David E. Shaw (collectively, the “Reporting Persons”) became the beneficial owners of more than 5% of the class of securities. On December 30, 2016, the Reporting Persons ceased to be beneficial owners of more than 5% of the class of securities. On January 4, 2017, the Reporting Persons again became beneficial owners of more than 5% of the class of securities. The beneficial ownership information provided in this document is current as of January 4, 2017.

**Item 1.**

**(a) Name of Issuer**

BioCryst Pharmaceuticals, Inc.

**(b) Address of Issuer's Principal Executive Offices**

4505 Emperor Blvd., Suite 200

Durham, NC 27703

**Item 2.**

**(a) Name of Person Filing**

D. E. Shaw & Co., L.P.

David E. Shaw

**(b) Address of Principal Business Office or, if none, Residence**

The business address for each reporting person is:

1166 Avenue of the Americas, 9th Floor

New York, NY 10036

**(c) Citizenship**

D. E. Shaw & Co., L.P. is a limited partnership organized under the laws of the state of Delaware.

David E. Shaw is a citizen of the United States of America.

**(d) Title of Class of Securities**

Common stock, par value \$0.01

**(e) CUSIP Number**

09058V103

**Item 3. If this statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:**

Not Applicable

**Item 4. Ownership**

As of January 4, 2017:

(a) Amount beneficially owned:

3,690,207 shares

D. E. Shaw &  
Co., L.P.:

This is composed of (i) 1,864,212 shares in the name of D. E. Shaw Valence Portfolios, L.L.C., (ii) 1,449,683 shares in the name of D. E. Shaw Oculus Portfolios, L.L.C., and (iii) 376,312 shares under the management of D. E. Shaw Investment Management, L.L.C.

3,690,207 shares

David E. Shaw:

This is composed of (i) 1,864,212 shares in the name of D. E. Shaw Valence Portfolios, L.L.C., (ii) 1,449,683 shares in the name of D. E. Shaw Oculus Portfolios, L.L.C., and (iii) 376,312 shares under the management of D. E. Shaw Investment Management, L.L.C.



(b) Percent of class:

D. E. Shaw & Co., L.P.: 5.0%  
David E. Shaw: 5.0%

(c) Number of shares to which the person has:

(i) Sole power to vote or to direct the vote:

D. E. Shaw & Co., L.P.: -0- shares  
David E. Shaw: -0- shares

(ii) Shared power to vote or to direct the vote:

D. E. Shaw & Co., L.P.: 3,652,607 shares  
David E. Shaw: 3,652,607 shares

(iii) Sole power to dispose or to direct the disposition of:

D. E. Shaw & Co., L.P.: -0- shares  
David E. Shaw: -0- shares

(iv) Shared power to dispose or to direct the disposition of:

D. E. Shaw & Co., L.P.: 3,690,207 shares  
David E. Shaw: 3,690,207 shares

David E. Shaw does not own any shares directly. By virtue of David E. Shaw's position as President and sole shareholder of D. E. Shaw & Co., Inc., which is the general partner of D. E. Shaw & Co., L.P., which in turn is the manager and investment adviser of D. E. Shaw Valence Portfolios, L.L.C., the investment adviser of D. E. Shaw Oculus Portfolios, L.L.C., and the managing member of D. E. Shaw Investment Management, L.L.C., and by virtue of David E. Shaw's position as President and sole shareholder of D. E. Shaw & Co. II, Inc., which is the managing member of D. E. Shaw & Co., L.L.C., which in turn is the manager of D. E. Shaw Oculus Portfolios, L.L.C., David E. Shaw may be deemed to have the shared power to vote or direct the vote of 3,652,607 shares, and the shared power to dispose or direct the disposition of 3,690,207 shares, the 3,690,207 shares as described above constituting 5.0% of the outstanding shares and, therefore, David E. Shaw may be deemed to be the beneficial owner of such shares. David E. Shaw disclaims beneficial ownership of such 3,690,207 shares.

**Item 5. Ownership of Five Percent or Less of a Class**

Not Applicable

**Item 6. Ownership of More than Five Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification**

By signing below, each of D. E. Shaw & Co., L.P. and David E. Shaw certify that, to the best of such reporting person's knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purposes or effect.

**SIGNATURE**

After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct. A Power of Attorney, dated January 1, 2017, granted by David E. Shaw in favor of Nathan Thomas, is attached hereto.

Dated: January 9, 2017

D. E. Shaw & Co., L.P.

By: /s/ Nathan Thomas  
Nathan Thomas  
Chief Compliance Officer

David E. Shaw

By: /s/ Nathan Thomas  
Nathan Thomas  
Attorney-in-Fact for David E. Shaw